Q3 2022

Filed Nov 9, 2022 · 10-Q · 40 days after period end · 0001062822-22-000042

Q3 2022 · 10-Q

Revenue

$0.00

— vs Q3 2021

Net Income

-$23.39M

N/M vs Q3 2021

EPS Diluted

-$0.13

N/M vs Q3 2021

Operating Income-$23,095,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	$0.00	$0.00	$0.00	$285.91M
Net Income	-$23.39M	-$23.12M	$82.60M	$226.09M
EPS Diluted	-$0.13	-$0.16	$0.71	$1.95

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR